fda-consultant-specialist

FDA submission pathway selection depends on your medical device classification and intended use, guiding the choice between 510(k), De Novo, or PMA. Evaluating predicate devices and analyzing risk assessments help align your product with the correct regulatory route.

The difference between 510(k), De Novo, and PMA submissions lies in risk level and predicate availability. 510(k) requires a predicate device, De Novo is for novel low-to-moderate risk devices without a predicate, and PMA applies to high-risk devices requiring clinical data validation.

Planning QSR compliance under 21 CFR 820 involves establishing quality system requirements across the medical device lifecycle. You generate documentation artifacts, conduct risk assessments, and integrate cybersecurity and HIPAA considerations to meet FDA expectations for manufacturing and post-market surveillance.

You need a De Novo classification instead of a 510(k) when your medical device is low-to-moderate risk but lacks a legally marketed predicate device. The De Novo pathway establishes a new regulatory classification, whereas 510(k) requires demonstrating substantial equivalence to an existing device.

Medical device submissions increasingly require cybersecurity and HIPAA considerations if the device handles patient data or connects to networks. Integrating these assessments into your risk management and documentation artifacts ensures compliance with FDA expectations across the product lifecycle.

Required documentation artifacts for 510(k) or PMA submissions include device descriptions, intended use statements, and comprehensive risk assessments. You must compile these artifacts to demonstrate substantial equivalence or safety and effectiveness, satisfying FDA submission requirements and QSR compliance planning.